Revenue for Q3 2025 was $58.3 million compared to $60.8 million for Q3 2024, representing a 4.1% decrease. This compares to revenue of $57.4 million in Q2 2025, reflecting a return to positive quarter ...

Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, ...